Kwality Pharmaceuticals Limited (KPL) Share Price
NSE · Healthcare · Drug Manufacturers - Specialty & Generic · ISIN INE552U01010
Key metrics
- Market Cap
- —
- P/E Ratio
- 43.47
- EPS
- 77.98
- Book Value
- 317.96
- P/B Ratio
- 10.66
- ROE
- 20.41%
- ROCE
- 21.37%
- Debt / Equity
- 0.4
- Net Margin
- 13.39%
- Revenue Growth
- 35.89%
- Profit Growth
- 69.02%
- Dividend Yield
- —
- 52W High
- ₹3,708.90
- 52W Low
- ₹3,230.10
- Market Cap Band
- —
- Face Value
- 10
Ratios computed from the annual results period ending 2026-03-31.
About Kwality Pharmaceuticals Limited
Kwality Pharmaceuticals Limited, together with its subsidiary, manufactures finished pharmaceutical formulations in India and internationally. The company offers its products in various dosage forms, including capsules, eye and ear drops, ointments and creams, pouches and sachets, sanitizers, tablets, suppositories, injectable vials and ampoules, liquid orals, lyophilized products, syrups, and various other categories, such as general, beta-lactam, cephalosporins, oncology, biologics, and hormones and specialty injectables. It also provides intermediates, chemicals, extracts, alkaloids, toilet requisites, beverages, and other medical preparations. Kwality Pharmaceuticals Limited was incorporated in 1983 and is based in Amritsar, India.
- Headquarters
- Amritsar, India
- Employees
- 1,137
- Promoter Holding
- 77.49%
The full Kwality Pharmaceuticals Limited analysis
Create a free account to open the complete KPL deep-dive — fourteen tabs of fundamental, technical, institutional and ownership data.
- 10-year financialsIncome statement, balance sheet and cash flow, year by year.
- Valuation & fair valueFair-value estimates, quality scores and a value grade.
- Charts & technicalsCandlestick charts, RSI, MACD, Supertrend and detected patterns.
- Shareholding historyPromoter, FII, DII and public holdings across every quarter.
- Ace investor holdingsWhich well-known investors hold it, and how their stake changed.
- Deals & insider tradesBulk and block deals, insider transactions and mutual-fund holdings.